Traditional analytical methods encounter challenges when quantifying busulfan, an antineoplastic cancer therapy, due to its bioavailability. UPLC-MS/MS analysis with the ACQUITY UPLC I-Class PLUS and Xevo TQD Mass Spectrometer provides clinical research laboratories with highly selective and accurate data, as well as and rapid analysis and increased sensitivity.
Busulfan is a bifunctional alkylating agent whose bioavailability varies greatly between individuals due to factors such as age, underlying diseases, and drug-drug interactions. An accurate, analytically sensitive and selective method may play a role in researching the pharmacokinetic and pharmacodynamic effects of busulfan administration. The ACQUITY UPLC I-Class PLUS and Xevo TQD provides the selectivity and sensitivity needed for greater accuracy.